A screening for specific biomarkers in serum of pancreatic cancer patients by SELDI technology
Author:
Affiliation:

Clc Number:

R 735.9

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Abstract:Objective:To explore the methode to screen for relatively specific markers in serum of pancreatic cancer patients using surface-enhanced laser desorption and ionization time of fight mass spectrometry(SELDI-TOF-MS).
    Methods :Serum samples from 20 pancreatic cancer patiants,20 healthy volunteers and 18 patients with other pancreatic diseases were examined. WCX magnetic beans and PBSⅡ-C protein chips reader (ciphergen Biosystems Ins.) were used to detect the protein fingerprint expression of all the serum samples, and the resulting profiles were analyzed with Biomarker Wizard system.
    Results:Four differently expressed potential biomarkers were identified with the relative molecular weights of 5 705Da,4 935Da,5 318Da and 3 243Da respectively. Compared with control group, two proteins with m/z 5 705Da and 5 318Da were down-regulated, and two proteins with m/z 4 935Da and 3 243Da were up-regulated in pancreatic cancers.
    Conclusions:SELDI technology is a quick, easy and practical method to screen for specific biomarkers in serum of patients with pancreatic cancer. Four different proteins identified in this study may be as specific serum biomarkers of pancreatic cancer.

    Reference
    Related
    Cited by
Get Citation

MA Ning, GE Chunlin, LUAN Fengming, HU Chaojun, LI Ning, LIU Yongfeng.A screening for specific biomarkers in serum of pancreatic cancer patients by SELDI technology [J]. Chin J Gen Surg,2008,17(3):10-245.
DOI:10.7659/j. issn.1005-6947.2008.03.010

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:January 01,1900
  • Revised:January 01,1900
  • Adopted:
  • Online: March 25,2008
  • Published: